Radiation Oncology

The radiation oncology specialty was founded in 1963 and is one of the earliest institutions in China to establish an oncology specialty. In 1995, it became a State Council-authorized master's degree-granting site; in 1997, it became a provincial key discipline under development, and in 2010, a doctoral degree-granting site. In 2014, the Department of Radiation Oncology was re-established as an independent department. The radiation oncology specialty currently has 3 wards, more than 140 open beds, more than 120 medical, nursing, and technical staff members, more than 20 staff members with senior professional titles, 1 doctoral supervisor, 12 master's supervisors, and 30 staff members holding doctoral degrees. It has been approved as a Shandong Provincial Clinical Key Specialty and a Qingdao Key Discipline in Oncology. It is currently a National Drug Clinical Research Base and a National Health Commission demonstration ward for standardized cancer pain management. It has 1 member of the Radiotherapy Committee of the Chinese Medical Doctor Association, 2 deputy chairs of the Radiotherapy Committee of the Shandong Medical Association, and 2 deputy chairs of the Radiotherapy Committee of the Shandong Medical Doctor Association; many physicians serve as committee members of various academic societies both in China and abroad. It has hosted major international and domestic academic conferences many times. The discipline leader, Director Lu Haijun, has considerable influence in China.

The Department of Radiation Oncology provides various cancer treatment modalities, including radiotherapy, chemotherapy, biological targeted therapy, interventional therapy, and others. Preoperative radiotherapy and chemotherapy can increase the tumor resection rate; postoperative adjuvant radiotherapy and chemotherapy reduce recurrence and metastasis and improve the cure rate; radiotherapy combined with interventional therapy improves the efficacy of local treatment; concurrent chemoradiotherapy improves tumor control and cure rates. It has 3 wards and 5 radiation treatment rooms. It has five of the world's most advanced linear accelerators, including TOMO, TrueBeam, and Trilogy, two imported iridium-192 afterloading radiotherapy machines, two imported large-bore CT simulation and positioning systems, and more than 10 complete sets of radiotherapy equipment, including treatment planning systems and dosimeters, reaching an advanced level in China. Dedicated dosimetry and maintenance personnel provide dose monitoring, clinical dose measurement, and maintenance support for the radiotherapy machines. Featured treatment techniques: three-dimensional conformal radiotherapy (3DCRT); intensity-modulated radiotherapy (IMRT); three-dimensional afterloading treatment technique; SBRT treatment (TrueBeam); and whole-body radiotherapy (TOMO). These treatment techniques enable more thorough treatment of tumors and more effective protection of surrounding normal tissues and organs, especially important tissues and organs within or near the target area, thereby effectively reducing complications.

Scope of diagnosis and treatment:

1. Head and neck tumors: nasopharyngeal carcinoma, tongue cancer, other oral cancers, malignant tumors of the nasal cavity, ethmoid sinus cancer, malignant tumors of the maxillary sinus, tonsillar cancer, laryngeal cancer, malignant salivary gland tumors, cancer of the external and middle ear, ocular tumors, and thyroid cancer. 2. Chest tumors: lung tumors (small-cell lung cancer, non-small-cell lung cancer, and pulmonary metastatic tumors), mediastinal tumors, chest wall and pleural tumors, esophageal cancer, cardia cancer, and breast cancer. 3. Abdominal malignant tumors: gastric cancer, colon cancer, pancreatic cancer, liver cancer, and biliary tract cancer. 4. Urinary system tumors: renal cancer, bladder cancer, prostate cancer, malignant testicular tumors, and penile cancer. 5. Female reproductive system tumors: cervical cancer, endometrial cancer, malignant ovarian tumors, malignant trophoblastic tumors, and vulvovaginal cancer. 6. Central nervous system tumors: malignant glioma, medulloblastoma, germ cell tumors, malignant lymphoma, deep brain tumors or tumors in major functional areas, and brain metastases. 7. Malignant tumors of the hematopoietic system: Hodgkin lymphoma, non-Hodgkin lymphoma, mycosis fungoides, malignant granuloma, multiple myeloma, and leukemia. 8. Soft-tissue tumors: soft-tissue sarcoma. 9. Primary malignant bone tumors: osteosarcoma, Ewing tumor, giant cell tumor of bone, bone lymphoma, chordoma, bone fibrosarcoma, vertebral hemangioma, and eosinophilic granuloma. 10. Skin cancer: malignant melanoma. 11. Treatment of metastatic tumors: bone metastases, brain metastases, liver metastases, and pulmonary metastatic lesions. 12. Some benign tumors or non-neoplastic diseases: scar hyperplasia, plantar warts, and others.